SAGE-718
718-CNA-202
Phase 2 small_molecule completed
Quick answer
SAGE-718 for Mild Cognitive Impairment is a Phase 2 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Indication
- Mild Cognitive Impairment
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed